Treatment-related adverse events and response rate to immune checkpoint inhibition

BACKGROUND: Immune checkpoint inhibition (ICI) represents a novel treatment modality for refractory cancers, and improving prediction of potential responders is critical. METHOD: We hypothesized that ICI is a systemic-effecting mechanism. The objective response rate (ORR) for anti-PD-1, anti-PD-L1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanmin, Wang, Zhengping, Guo, Ting, Liu, Shenghua, Feng, Chenchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783260/
https://www.ncbi.nlm.nih.gov/pubmed/31777292
http://dx.doi.org/10.1177/0300060519886454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783260/
https://www.ncbi.nlm.nih.gov/pubmed/31777292
http://dx.doi.org/10.1177/0300060519886454

Ejemplares similares